Hyperfine, Inc. (HYPR): Total Liabilities
$14.26M
As of 2025-12-31
$26.24M
As of 2026-06-30
+11.3%
3-year compound annual growth
+27.1%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $14.26M | +44.6% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $9.86M | +0.6% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $9.80M | -5.1% | 2025-03-17, Balance as of period end |
| 2022-12-31 | $10.33M | -36.4% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $16.25M | +278.3% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $4.29M | n/a | 2022-03-25, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Hyperfine, Inc. (HYPR) | 2025-12-31 | $14.26M | +44.6% |
| CapsoVision, Inc (CV) | 2025-12-31 | $4.90M | +82.4% |
| Escalon Medical Corp (ESMC) | 2026-06-30 | $3.20M | +4.0% |
| QT Imaging Holdings, Inc. (QTI) | 2025-12-31 | $16.58M | +6.1% |
| Nuwellis, Inc. (NUWE) | 2025-12-31 | $3.49M | +4.6% |
| Precision Optics Corporation, Inc. (POCI) | 2026-06-30 | $11.99M | +59.1% |
| electroCore, Inc. (ECOR) | 2025-12-31 | $20.38M | +57.6% |
| Stereotaxis, Inc. (STXS) | 2025-12-31 | $33.53M | -5.0% |
| Neuraxis, Inc (NRXS) | 2025-12-31 | $3.00M | +11.7% |
Compare HYPR, CV, ESMC, QTI side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗